**Currently Active Studies**

**Crohn's Disease:**

**(CELGENE)Ozanimod**

**A Phase 3, multicenter, randomized, double-blind, placebo-controlled study of oral ozanimod as induction therapy for moderately to severe crohn's disease patients**

**(GENENTECH) Etro studies: BERGAMOT**

**A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of etrolizumab as an induction and maintenance treatment for patients with moderately to severely active crohn's disease.**

**Ulcerative Colitis:**

**(SERES) ECO-RESET**

**A Phase 2B, randomized, double-blind, placebo-controlled, multiple dose, multicenter study to assess efficacy and safety of SER-287 in adults with active mild-to-moderate Ulcerative Colitis.**

**C-DIFF:**

**(FINCH)CDI-001**

**A Multicenter, double-blind, parallel-arm, placebo-controlled, phase 2 study of the efficacy, safety and tolerability of oral full-spectrum microbiota (CP101) in subjects with recurrence of Clostridium Difficle infection.**

**(REBIOTIX) PUNCH CD3**

**The PUNCH CD 3 study is a Phase 3 clinical study to evaluate the safety and efficacy of Rebiotix RBX2660 for the prevention of recurrent *Clostridium difficile* infection (CDI).**

**PBC:**

**(CYMABAY) CB8025-31735**

**A 52 week, placebo-controlled, randomized, phase 3 study to evaluate the safety and efficacy of seladelphar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA).**

**NASH:**

**(INTERCEPT) Regenerate Study**

**REGENERATE (Randomized Global Phase 3 Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment) is a randomized, double-blind, placebo-controlled, multicenter trial. It is assessing the safety and potential benefit of OCA on liver-related clinical outcomes in NASH patients with fibrosis.**

**SAMPLE COLLECTION / REGISTRY STUDIES:**

**PROMETHEUS 16HEP01 (NASH)**

**Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test.**

**ABBVIE- LEGACY (Ulcerative Colitis)**

**A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC).**

**SHIRE- Short Bowel Registry**

**A global prospective, observational, multi-center registry to evaluate the long-term safety profile for participants with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in participants with SBS. SBS participants treated and not treated with teduglutide will be enrolled.**